Raltegravir
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB06817 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 17 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | feline acquired immunodeficiency syndrome | KG + DL |
| 2 | simian immunodeficiency virus infection | KG + DL |
| 3 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | KG + DL |
| 4 | AIDS related complex | KG + DL |
| 5 | congenital human immunodeficiency virus | KG + DL |
| 6 | obsolete familial combined hyperlipidemia | KG + DL |
| 7 | fibroma of prostate | KG + DL |
| 8 | breast fibrocystic disease | KG + DL |
| 9 | benign reproductive system neoplasm | KG + DL |
| 10 | Brenner tumor | KG + DL |
| 11 | benign prostate phyllodes tumor | KG + DL |
| 12 | apocrine adenosis of breast | KG + DL |
| 13 | blunt duct adenosis of breast | KG + DL |
| 14 | male reproductive organ cancer | KG + DL |
| 15 | prostate cancer/brain cancer susceptibility | KG + DL |
| 16 | benign mammary dysplasia | KG + DL |
| 17 | prostate leiomyoma | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.